Cargando…

A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis

PURPOSE: To evaluate the clinical efficacy and safety of a 1% azithromycin–0.1% dexamethasone combination in DuraSite (“combination”) compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis. MATERIALS AND METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseini, Kamran, Lindstrom, Richard L, Foulks, Gary, Nichols, Kelly K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986906/
https://www.ncbi.nlm.nih.gov/pubmed/27570444
http://dx.doi.org/10.2147/OPTH.S110739
_version_ 1782448238375206912
author Hosseini, Kamran
Lindstrom, Richard L
Foulks, Gary
Nichols, Kelly K
author_facet Hosseini, Kamran
Lindstrom, Richard L
Foulks, Gary
Nichols, Kelly K
author_sort Hosseini, Kamran
collection PubMed
description PURPOSE: To evaluate the clinical efficacy and safety of a 1% azithromycin–0.1% dexamethasone combination in DuraSite (“combination”) compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis. MATERIALS AND METHODS: This was a Phase III, double-masked, vehicle-controlled, four-arm study in which 907 subjects with blepharitis were randomized to combination (n=305), 0.1% dexamethasone (n=298), 1% azithromycin (n=155), or vehicle (n=149). Ten study visits were scheduled: screening visit, days 1 and 4 (dosing phase) and 15, and months 1–6 (follow-up phase). On day 1, subjects applied one drop of the study drug to the eyelid of the inflamed eye(s) twice daily, and continued with twice-daily dosing for 14 days. After completing 14 days of dosing, subjects were followed for 6 months for efficacy and safety. RESULTS: A total of 57 subjects (6.3%) had complete clinical resolution at day 15: 25 (8.2%), 17 (5.7%), 8 (5.2%), and 7 (4.7%) subjects in the combination-, 0.1% dexamethasone-, 1% azithromycin-, and vehicle-treatment groups, respectively. The combination was superior to 1% azithromycin and vehicle alone, but not to 0.1% dexamethasone alone. Mean composite (total) clinical sign and symptom scores improved in all four treatment groups during the post-treatment evaluation phase for the intent-to-treat population, but outcomes were superior when a drop containing 0.1% dexamethasone was utilized. Clinical response was noted as early as day 4, and persisted as long as 6 months. Most adverse events were considered mild in severity and not related to the study drug. CONCLUSION: A higher percentage of subjects in the combination group achieved complete clinical resolution of the signs and symptoms of blepharitis at day 15 than with 1% azithromycin and vehicle, but outcomes were similar to treatment with 0.1% dexamethasone alone. The combination was well tolerated.
format Online
Article
Text
id pubmed-4986906
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49869062016-08-26 A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis Hosseini, Kamran Lindstrom, Richard L Foulks, Gary Nichols, Kelly K Clin Ophthalmol Original Research PURPOSE: To evaluate the clinical efficacy and safety of a 1% azithromycin–0.1% dexamethasone combination in DuraSite (“combination”) compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis. MATERIALS AND METHODS: This was a Phase III, double-masked, vehicle-controlled, four-arm study in which 907 subjects with blepharitis were randomized to combination (n=305), 0.1% dexamethasone (n=298), 1% azithromycin (n=155), or vehicle (n=149). Ten study visits were scheduled: screening visit, days 1 and 4 (dosing phase) and 15, and months 1–6 (follow-up phase). On day 1, subjects applied one drop of the study drug to the eyelid of the inflamed eye(s) twice daily, and continued with twice-daily dosing for 14 days. After completing 14 days of dosing, subjects were followed for 6 months for efficacy and safety. RESULTS: A total of 57 subjects (6.3%) had complete clinical resolution at day 15: 25 (8.2%), 17 (5.7%), 8 (5.2%), and 7 (4.7%) subjects in the combination-, 0.1% dexamethasone-, 1% azithromycin-, and vehicle-treatment groups, respectively. The combination was superior to 1% azithromycin and vehicle alone, but not to 0.1% dexamethasone alone. Mean composite (total) clinical sign and symptom scores improved in all four treatment groups during the post-treatment evaluation phase for the intent-to-treat population, but outcomes were superior when a drop containing 0.1% dexamethasone was utilized. Clinical response was noted as early as day 4, and persisted as long as 6 months. Most adverse events were considered mild in severity and not related to the study drug. CONCLUSION: A higher percentage of subjects in the combination group achieved complete clinical resolution of the signs and symptoms of blepharitis at day 15 than with 1% azithromycin and vehicle, but outcomes were similar to treatment with 0.1% dexamethasone alone. The combination was well tolerated. Dove Medical Press 2016-08-10 /pmc/articles/PMC4986906/ /pubmed/27570444 http://dx.doi.org/10.2147/OPTH.S110739 Text en © 2016 Hosseini et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hosseini, Kamran
Lindstrom, Richard L
Foulks, Gary
Nichols, Kelly K
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title_full A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title_fullStr A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title_full_unstemmed A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title_short A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
title_sort randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986906/
https://www.ncbi.nlm.nih.gov/pubmed/27570444
http://dx.doi.org/10.2147/OPTH.S110739
work_keys_str_mv AT hosseinikamran arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT lindstromrichardl arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT foulksgary arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT nicholskellyk arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT hosseinikamran randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT lindstromrichardl randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT foulksgary randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis
AT nicholskellyk randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycin01dexamethasonecombinationcomparedto1azithromycinalone01dexamethasonealoneandvehicleinthetreatmentofsubjectswithblepharitis